Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study

Trial Profile

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
  • Indications Venous thromboembolism
  • Focus Adverse reactions
  • Acronyms COBRRA
  • Most Recent Events

    • 04 Apr 2017 Planned End Date changed from 1 Apr 2017 to 1 Sep 2017.
    • 04 Apr 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Sep 2017.
    • 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top